BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38384810)

  • 1. Clinical significance of serum high sensitive C-reactive protein/albumin ratio in primary prostate biopsy.
    Chen X; Li Y; Li G; Zhang X; Xie G; Huang Y; Yin H
    Front Oncol; 2024; 14():1325524. PubMed ID: 38384810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of inflammatory factors in prediction of Gleason score and its upgrading in localized prostate cancer patients after radical prostatectomy.
    Wang S; Ji Y; Ma J; Du P; Cao Y; Yang X; Yu Z; Yang Y
    Front Oncol; 2022; 12():1079622. PubMed ID: 36713540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urban-Rural Differences in Clinical Characteristics of Prostate Cancer at Initial Diagnosis: A Single-Center Observational Study in Anhui Province, China.
    Song QL; Qian Y; Min X; Wang X; Wu J; Li X; Yu Y
    Front Oncol; 2021; 11():704645. PubMed ID: 34414112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of serum free prostate-specific antigen density in the diagnosis of prostate cancer.
    Zou BZ; Wen H; Luo HJ; Luo WC; Xie QT; Zhou MT
    Ir J Med Sci; 2023 Dec; 192(6):2681-2687. PubMed ID: 37414978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of age on prostate cancer screening index.
    Shan J; Liu Z; Geng X; Feng Y; Yang X; Xu H; Zhou X; Ma W; Zhu H; Shi H
    J Clin Lab Anal; 2022 Jan; 36(1):e24098. PubMed ID: 34816496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study.
    Mearini L; Ferri C; Lazzeri M; Bini V; Nunzi E; Fiorini D; Costantini E; Manasse GC; Porena M
    Urol Int; 2014; 93(2):135-45. PubMed ID: 24732975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
    Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
    Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
    [No Abstract]   [Full Text] [Related]  

  • 12. The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6.
    Wang H; Gu L; Wu Y; Feng D; Duan J; Wang X; Huang Y; Wu S; Chen J; Luo G; Zhang X
    BMC Cancer; 2017 Sep; 17(1):629. PubMed ID: 28874127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of prostate volume on clinical parameters in prostate cancer screening.
    Shan J; Geng X; Lu Y; Liu Z; Zhu H; Zhou R; Zhang Z; Gang X; Zhang D; Shi H
    J Clin Lab Anal; 2022 Oct; 36(10):e24700. PubMed ID: 36098911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.
    Chen M; Ma T; Li J; Zhang HJ; Li Q; Wang JJ; Sang T; Cao CL; Cui XW
    Med Sci Monit; 2021 Feb; 27():e929913. PubMed ID: 33556045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate Cancer Predictive Simulation Modelling, Assessing the Risk Technique (PCP-SMART): Introduction and Initial Clinical Efficacy Evaluation Data Presentation of a Simple Novel Mathematical Simulation Modelling Method, Devised to Predict the Outcome of Prostate Biopsy on an Individual Basis.
    Spyropoulos E; Kotsiris D; Spyropoulos K; Panagopoulos A; Galanakis I; Mavrikos S
    Clin Genitourin Cancer; 2017 Feb; 15(1):129-138.e1. PubMed ID: 27460552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does genotyping of risk-associated single nucleotide polymorphisms improve patient selection for prostate biopsy when combined with a prostate cancer risk calculator?
    Butoescu V; Ambroise J; Stainier A; Dekairelle AF; Gala JL; Tombal B
    Prostate; 2014 Apr; 74(4):365-71. PubMed ID: 24265090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
    Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
    Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-specific prostate specific antigen cutoffs for guiding biopsy decision in Chinese population.
    Na R; Wu Y; Xu J; Jiang H; Ding Q
    PLoS One; 2013; 8(6):e67585. PubMed ID: 23825670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AI-predicted mpMRI image features for the prediction of clinically significant prostate cancer.
    Li S; Wang KX; Li JL; He Y; Wang XY; Tang WR; Xie WH; Zhu W; Wu PS; Wang XP
    Int Urol Nephrol; 2023 Nov; 55(11):2703-2715. PubMed ID: 37553543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of extraprostatic extension in patients with clinically organ-confined prostate cancer.
    Lin S; Zhang Q; Li P; Li Z; Sun Y; Shao Y; Zhang X; Fu S
    Urol Int; 2014; 92(3):282-8. PubMed ID: 24280781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.